| 2024-04-23 | +0.14 % |
- Summary: Marsh & McLennan (MMC) subsidiary, Marsh McLennan Agency, has entered into an agreement to acquire Fisher Brown Bottrell Insurance, Inc., boosting MMC stock by 0.14% following the announcement.
Reason for Stock Increase: The acquisition of Fisher Brown Bottrell Insurance, Inc. by Marsh McLennan Agency is seen as a positive move to expand its presence in the Southeast region, providing growth opportunities and enhancing risk management and benefit offerings for businesses and individuals, leading to the increase in MMC stock value.
- The article discusses how Commerzbank Aktiengesellschaft FI has acquired a new position in shares of Marsh & McLennan Companies, Inc. (MMC), leading to an increase in the stock price, with large institutional investors buying and selling shares as well as some insiders selling shares. The increased interest from institutional investors and positive quarterly earnings report may have contributed to the stock's rise.
- The article announces that Marsh & McLennan Agency LLC has acquired Fisher Brown Bottrell Insurance, Inc., leading to a 0.14% increase in Marsh & McLennan stock; the stock likely rose due to this acquisition expanding Marsh & McLennan's presence in the Southeast region and providing access to new resources, clients, and opportunities.
|
| 2024-04-22 | -0.48 % |
|
| 2024-04-19 | +0.34 % |
- The article discusses how Marsh & McLennan Companies, Inc. (MMC) stock went up by 0.34% following RBC Capital Markets' increased price target to $210 based on the company's organic growth acceleration, particularly in its Marsh and Oliver Wyman segments, and expectations of solid top-line momentum supported by potential mergers and acquisitions opportunities, ongoing restructuring program, and strong financial planning, indicative of its financial health and commitment to returning value to shareholders.
- The article discusses Keefe, Bruyette & Woods increasing Marsh & McLennan's price target to $195 and revising their estimates for operating earnings per share upwards due to the company's strong performance in the first quarter of 2024, which exceeded expectations, leading to the stock going up by 0.34%, despite concerns over slowing primary property and casualty rate increases affecting investor sentiment.
- The article discusses how Marsh & McLennan Companies, Inc. (MMC) stock rose by 0.34% after Wells Fargo adjusted its price target to $213 and highlighted the company's improved organic revenue growth, particularly in the U.S. and Canada markets, which increased from 5% to 8%. Despite weaker margins, the stock's performance was positively influenced by the growth projections and outlook for the rest of the year. Wells Fargo anticipates further margin enhancement and suggests that near-term movement will depend on how the company's results compare to its peers. The company's strong dividend growth, financial stability, and consistent profitability over the years also contribute to its attractiveness to investors. MMC's market capitalization is reported at $99.45 billion, with a P/E ratio of 25.09 and a Price/Book ratio of 7.88, signaling a premium valuation compared to the industry average, but the solid revenue growth of 10.38% indicates strong financial performance.
|
| 2024-04-18 | +2.08 % |
- The article provides updates on various company stocks, including Marsh & McLennan (MMC), which was up by 2.08%. MMC stock likely increased due to positive market sentiments, company performance, and possible investor optimism.
- Marsh & McLennan (MMC) stock was up 2.08% last night; the increase can be attributed to the company reporting strong financial results in the first quarter of 2024, including a 9% growth in revenue, 14% growth in adjusted EPS, and positive performance across its risk & insurance services, consulting, and other segments, positioning the company for a successful year ahead.
- The article discusses the recent 2.08% increase in Marsh & McLennan Companies (MMC) stock, with Piper Sandler downgrading the rating to neutral, leading to varied target price predictions by different research firms, and hints at the stock increase potentially being influenced by factors such as quarterly earnings results, dividends, and insider selling activities.
|
| 2024-04-11 | -0.99 % |
|
| 2024-04-10 | -1.54 % |
|
| 2024-04-09 | +0.02 % |
|
| 2024-04-08 | -0.63 % |
|
| 2024-04-01 | -1.01 % |
|
| 2024-03-28 | +0.18 % |
|
| 2024-03-27 | +1.1 % |
|
| 2024-03-26 | +0.14 % |
|
| 2024-03-25 | -0.66 % |
|
| 2024-03-22 | -0.49 % |
- The article provides insights into Marsh & McLennan Companies, Inc. (MMC) stock performance, including analyst recommendations and recent updates, stating that last night, the stock was down by -0.49%. The stock went down due to various factors, such as analyst reports rating it as "sell" or "hold," with price targets being adjusted lower, company insiders selling shares, and institutional investors buying and selling shares.
- The article relates to the upcoming 2024 Annual General Meeting (AGM) of Intertek Group plc and provides information regarding the resolutions that will be proposed, such as the approval of financial reports and directors' remuneration policies. Marsh & McLennan (MMC) stock went down likely due to various factors influencing the stock market, such as market conditions, economic data, company performance, or general investor sentiments.
|
| 2024-03-21 | -0.49 % |
- The article discusses Marsh McLennan (NYSE: MMC) announcing the release of its first-quarter financial results, with a teleconference scheduled to discuss the results led by the President and CEO John Doyle and CFO Mark McGivney; the stock was down by -0.49% last night. The reason behind the decrease in Marsh & McLennan stock might be influenced by various factors such as overall market conditions, company performance expectations, industry trends, economic indicators, or specific news related to the company.
- The article is about Marsh & McLennan (MMC) announcing first-quarter financial results on April 18, 2024, and hosting a teleconference with investors led by their President and CEO and CFO, but last night the stock was down by -0.49%. The stock may have gone down due to factors such as market conditions, investor sentiment, or specific company performance concerns.
|
| 2024-03-20 | -0.11 % |
|
| 2024-03-18 | +0.27 % |
|
| 2024-03-15 | -0.67 % |
- The article discusses that Marsh & McLennan Companies, Inc. (MMC) stock was down by 0.67% due to the announcement of a quarterly dividend, raising concerns among investors, with financial indicators showing a strong performance and dividend coverage, while factors like insider selling and analyst ratings might also be contributing to the stock decrease.
- The article discusses Raleigh Capital Management Inc. increasing its stake in Marsh & McLennan Companies, Inc. and other institutional investors modifying their holdings as well as insider selling of company stock, but despite positive earnings results, the stock declined by -0.67% likely influenced by recent analyst downgrades.
- Summary: Marsh & McLennan Companies, Inc. (NYSE:MMC) saw its stock down by -0.67% last night, with institutional investors like Raleigh Capital Management Inc. increasing their stake, while several brokerages provided a mix of rating actions for the company. The stock went down likely due to the sell-off by insiders, with CEO Dean Michael Klisura selling a significant number of shares in March.
Reason for stock decline: The stock likely went down due to insider selling, with CEO Dean Michael Klisura and CMO John Jude Jones selling a considerable number of shares, causing investors to react negatively to the sell-off by company insiders.
|
| 2024-03-13 | +0.27 % |
|
| 2024-03-12 | +0.67 % |
|
| 2024-03-06 | +0.86 % |
|
| 2024-03-01 | -0.13 % |
- The article discusses Marsh McLennan Agency's completion of acquisitions of two Louisiana-based middle-market agencies, Querbes & Nelson and Louisiana Companies, which has doubled its presence in Louisiana, and provides information about the executives leading these newly acquired companies. Marsh & McLennan's stock went down due to factors such as overall market conditions, investor sentiment, company performance, or external events impacting the industry.
- Summary: Marsh McLennan (MMC) stock experienced a -0.13% decrease, and the company, in a public-private partnership with the Ukrainian government and Lloyd’s, expanded its Unity insurance facility to provide affordable war risk insurance for non-military cargo, aiming to support Ukraine's export trade.
Reason for MMC stock decrease: The decrease in stock value is likely not directly related to the expanded insurance initiative with the Ukrainian government, as stock value fluctuates due to various factors like market conditions, investor sentiment, company performance, and economic indicators.
|
| 2024-02-29 | -1.85 % |
|
| 2024-02-28 | +1.4 % |
|
| 2024-02-27 | -0.13 % |
|
| 2024-02-26 | -0.07 % |
|
| 2024-02-23 | -0.3 % |
- Summary: Marsh & McLennan Companies, Inc. (MMC) stock was down -0.3% following an average "Hold" rating by fourteen coverage firms and mixed recommendations with two sell, eight hold, and four buy ratings; the stock experienced analyst downgrades from companies like StockNews.com and Goldman Sachs Group, resulting in decreased price targets impacting stock performance.
Reason for stock decline: The stock might have gone down due to analyst downgrades from firms like StockNews.com and Goldman Sachs Group, as well as a cut in price targets, impacting investor sentiment and stock performance.
- The article discusses Marsh & McLennan Companies, Inc. (MMC) stock, which was down 0.3% last night due to analysts issuing mixed recommendations, including some downgrades and price target adjustments, as well as changes in hedge fund positions, despite the company reporting positive quarterly earnings with revenue beating expectations.
|
| 2024-02-20 | +0.29 % |
|
| 2024-02-14 | +0.64 % |
|
| 2024-02-06 | +1.18 % |
|
| 2024-02-05 | -0.58 % |
|
| 2024-02-02 | -0.2 % |
|
| 2024-02-01 | -0.05 % |
|
| 2024-01-31 | +0.42 % |
|
| 2024-01-30 | +1.07 % |
|
| 2024-01-26 | +0.99 % |
|
| 2024-01-25 | -3.83 % |
|
| 2024-01-23 | +0.34 % |
|
| 2024-01-18 | +1.09 % |
|
| 2024-01-10 | +0.71 % |
|
| 2024-01-02 | +0.37 % |
|
| 2023-12-18 | +1.41 % |
|
| 2023-12-12 | +1.26 % |
- The article discusses the recent performance of Arthur J. Gallagher & Co. stock and highlights that it underperformed compared to competitor Marsh & McLennan Cos., which saw a 1.26% increase in its stock price. The reasons for the increase in Marsh & McLennan stock are not stated in the article.
- Marsh & McLennan (MMC) stock went up by 1.26% following the announcement that its unit, Oliver Wyman, will acquire SeaTec Consulting, a company specializing in consulting, engineering, and digital expertise in industries such as aviation and defense. This acquisition is expected to close in the first quarter and SeaTec will join CAVOK, another division of Oliver Wyman focused on aviation services. This acquisition follows Oliver Wyman's previous acquisition of Avascent in November 2022. Additionally, Marsh & McLennan's unit Mercer recently agreed to acquire Vanguard Group's outsourced chief investment officer business.
- Marsh & McLennan's stock (MMC) went up by 1.26% due to the announcement that Oliver Wyman, a business of Marsh McLennan, is acquiring SeaTec Consulting Inc., a leading provider of consulting, engineering, and digital expertise in the aviation, aerospace, defense, and transportation industries, which will further establish Oliver Wyman as a leader in these sectors.
|
| 2023-12-05 | -0.51 % |
|
| 2023-11-30 | +1.57 % |
|
| 2023-11-28 | -1.49 % |
|
| 2023-11-27 | -0.34 % |
|
| 2023-11-21 | +0.19 % |
|
| 2023-11-17 | -0.23 % |
- The article discusses the reasons behind the decline in Marsh & McLennan (MMC) stock. The main reason for the decline is the rise in healthcare costs, particularly in pharmacy benefit costs, which have been increasing steadily. Additionally, the article mentions that the cost increases are projected to continue in the future. Prescriptions drugs, especially those used for the treatment of diabetes and obesity, have been the fastest-growing component of health benefit cost. These drugs are expensive and their utilization has increased, leading to higher costs for health plans. Furthermore, the article mentions that new gene and cell therapies are also beginning to impact cost, as they are one-time, high-cost treatments. Despite the rising health plan costs, large employers have not shifted additional costs to employees through higher deductibles, copays, or out-of-pocket maximums. Instead, they are focusing on cost management strategies that do not shift additional costs to employees, such as steering patients to higher-quality care and providing more intensive care management.
|
| 2023-11-16 | +1.45 % |
|
| 2023-11-15 | -1.32 % |
|
| 2023-11-14 | -1.04 % |
|
| 2023-11-09 | +0.6 % |
|
| 2023-11-03 | +0.25 % |
|
| 2023-11-02 | +1.79 % |
|
| 2023-10-31 | +0.73 % |
|
| 2023-10-30 | +1.82 % |
|
| 2023-10-27 | -1.19 % |
|
